SCM
CLVS

Sigma Capital Management’s Clovis Oncology, Inc. CLVS Stock Holding History

Sigma Capital Management’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-20,000
Closed -$1.39M – 121
2014
Q1 		$1.39M Buy
+20,000
New +$1.47M 0.07% 144
2013
Q4 		– Sell
-60,000
Closed -$3.65M – 283
2013
Q3 		$3.65M Buy
60,000
+10,000
+20% +$709K 0.15% 164
2013
Q2 		$3.35M Buy
+50,000
New +$2.25M 0.15% 137

Other funds holding CLVS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return

Sigma Capital Management's CLVS Position: Q2 2014 in Review

Sigma Capital Management sold out of Clovis Oncology, Inc. (CLVS) in Q2 2014, closing a stake of 20,000 shares — an estimated $1.39M sold.

Sigma Capital Management first reported a position in CLVS in Q2 2013 and held it in 3 quarters. The position peaked at $3.65M in Q3 2013. 140 funds tracked by Wall St. Rank hold CLVS as of Q2 2014.

  • Sigma Capital Management reported no remaining Clovis Oncology, Inc. position as of Q2 2014 after selling out during the quarter.
  • Sigma Capital Management sold 20,000 Clovis Oncology, Inc. shares in Q2 2014, an estimated $1.39M.
  • Sigma Capital Management first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 3 quarters.
  • Sigma Capital Management's Clovis Oncology, Inc. position peaked at $3.65M in Q3 2013.
  • 140 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2014.

Based on Sigma Capital Management's 13F filing for Q2 2014.